Basic understanding of current classification and management of retinoblastoma
Basic understanding of current classification and management of retinoblastoma
复制标题
DOI：
10.1097/01.icu.0000193079.55240.18
复制
发表时间：
2006-06-01
影响因子：
3.7
通讯作者：
Shields, Jerry A.
中科院分区：
文献类型：
--
作者：
Shields, Carol L.;Shields, Jerry A.
综述目的讨论当前视网膜母细胞瘤的分类和管理策略。最新发现视网膜母细胞瘤国际分类是视网膜母细胞瘤的新分类系统，基于肿瘤大小、位置和相关种植：A 组 = 视网膜母细胞瘤大小不超过 3 毫米； B组=视网膜母细胞瘤大小超过3毫米、位于黄斑区或少量视网膜下液； C组=具有局部种子的视网膜母细胞瘤； D组=具有弥漫性种子的视网膜母细胞瘤； E组=需要摘除的巨大视网膜母细胞瘤。这种分类旨在简化分组并帮助预测治疗结果。化学减容是双侧视网膜母细胞瘤和某些单侧视网膜母细胞瘤的重要治疗方法。视网膜母细胞瘤的国际分类可以可靠地预测化疗效果，A 组病例为 100%，B 组病例为 93%，C 组病例为 90%，D 组病例为 4710 例。 E 组通常采用摘除术进行治疗。总结视网膜母细胞瘤的新分类可以更好地判断视网膜母细胞瘤化疗是否成功。
Purpose of reviewThe current classification and management strategies for retinoblastoma are discussed.Recent findingsThe International Classification of Retinoblastoma is a new classification system for retinoblastoma and is based on tumor size, location, and associated seeding: group A=retinoblastoma up to 3 mm in size; group B=retinoblastoma more than 3 mm in size, macular location, or minor subretinal fluid; group C=retinoblastoma with localized seeds; group D=retinoblastoma with diffuse seeds; and group E=massive retinoblastoma necessitating enucleation. This classification was designed to simplify grouping and to assist in predicting treatment outcomes. Chemoreduction is an important therapy for bilateral retinoblastoma: and some cases of unilateral retinoblastoma. This International Classification of Retinoblastoma can reliably predict chemoreduction outcome, as success was achieved in 100% of group A, 93% of group B, 90% of group C, and 4710 of group D cases. Group E is typically managed with enucleation.SummaryThe new classification of retinoblastoma allows better judgement for success with chemoreduction for retinoblastoma.